ACE2 inhibitors for treatment of COVID-19

Inhibitors that prevent the interaction of the SARS-CoV-2 virus with the ACE2 receptor or prevent its internalisation may be candidate antiviral agents for COVID. We will screen ACE2 inhibitors for their ability to prevent viral entry and replication, examine their mechanisms of action and optimise the best candidates for formulation as an inhalant to treat patients with Acute Respiratory Distress Syndrome.

Objective

Our work aims to contribute to the development of an antiviral inhalant to treat patients with Acute Respiratory Distress Syndrome caused by SARS-CoV-2 infection (COVID).

Approach

We will screen ACE2 inhibitors for their ability to prevent cell entry and replication of SARS-CoV-2, examine their mechanism of action and optimise the best performing candidates for formulation as an inhalant to treat patients with Acute Respiratory Distress Syndrome.